193 related articles for article (PubMed ID: 30422238)
41. Gene-environment interaction between APOA5 c.553G>T and pregnancy in hypertriglyceridemia-induced acute pancreatitis.
Pu N; Yang Q; Shi XL; Chen WW; Li XY; Zhang GF; Li G; Li BQ; Ke L; Tong ZH; Cooper DN; Chen JM; Li WQ; Li JS
J Clin Lipidol; 2020; 14(4):498-506. PubMed ID: 32561169
[TBL] [Abstract][Full Text] [Related]
42. The Association Between APOA5 Gene Polymorphisms and Plasma Lipids in the Turkish Cypriot Population: A Possible Biomarker for Preventing Cardiovascular Diseases.
Fahrioğlu U; Ergören MÇ
Biochem Genet; 2018 Jun; 56(3):176-187. PubMed ID: 29264753
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
[TBL] [Abstract][Full Text] [Related]
45. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
46. Common genetic variants contribute to primary hypertriglyceridemia without differences between familial combined hyperlipidemia and isolated hypertriglyceridemia.
De Castro-Orós I; Cenarro A; Tejedor MT; Baila-Rueda L; Mateo-Gallego R; Lamiquiz-Moneo I; Pocoví M; Civeira F
Circ Cardiovasc Genet; 2014 Dec; 7(6):814-21. PubMed ID: 25176936
[TBL] [Abstract][Full Text] [Related]
47. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
[TBL] [Abstract][Full Text] [Related]
48. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
Wong SF
Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
[TBL] [Abstract][Full Text] [Related]
49. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
50. Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes.
Vrablik M; Hubacek JA; Dlouha D; Satny M; Adamkova V; Ceska R
Folia Biol (Praha); 2019; 65(4):188-194. PubMed ID: 31903892
[TBL] [Abstract][Full Text] [Related]
51. Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia.
Esteve-Luque V; Padró-Miquel A; Fanlo-Maresma M; Corbella E; Corbella X; Pintó X; Candás-Estébanez B
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33567543
[TBL] [Abstract][Full Text] [Related]
52. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
53. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Feb; ():. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
54. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Apr; ():. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
55. APOA5 -1131T>C and APOC3 -455T>C polymorphisms are associated with an increased risk of coronary heart disease.
Sun Y; Zhou RB; Chen DM
Genet Mol Res; 2015 Dec; 14(4):18218-28. PubMed ID: 26782469
[TBL] [Abstract][Full Text] [Related]
56. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.
Talmud PJ; Cooper JA; Hattori H; Miller IP; Miller GJ; Humphries SE
Diabetologia; 2006 Oct; 49(10):2337-40. PubMed ID: 16917759
[TBL] [Abstract][Full Text] [Related]
57. Association of APOA5 -1131T>C polymorphism and serum lipid levels in patients with type 2 diabetes.
Celap I; Simundic AM; Nikolac N; Kackov S; Katalinic D
DNA Cell Biol; 2013 Oct; 32(10):589-93. PubMed ID: 23919616
[TBL] [Abstract][Full Text] [Related]
58. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
59. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
60. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
